Endeavor Health Unveils Advanced Genetic Screening for Heart Disease Risk Assessment

Comprehensive Genetic Screening Revolutionizes Heart Disease Risk Assessment

Endeavor Health has recently introduced a pioneering genetic test aimed at improving the prediction of coronary artery disease (CAD) risks. Launched in June 2026, the GenProb-CAD test offers a significant advancement by integrating both monogenic and polygenic risk factors into one assessment tool. This emerging innovation is designed exclusively for patients within the Endeavor Health network and stems from an extensive study published in Circulation Genomic and Precision Medicine.

The Need for Enhanced Screening

Heart disease remains the leading cause of mortality in the United States, accounting for nearly 1 million deaths in just one year. Despite advancements in diagnostic techniques, many individuals remain undiagnosed until it is too late. Current approaches mainly rely on two types of genetic tests: monogenic tests that focus on rare gene variations, and polygenic tests which estimate risks based on minor variations across a broad range of genes. The newly developed GenProb-CAD test promises a more holistic view by combining the strengths of both methods—mapping the genetic landscape of coronary artery disease and inherited high cholesterol risk through Lipoprotein(a).

Insights from the Research

This groundbreaking test is supported by the analysis of biobank data from approximately 450,000 individuals. According to Jianfeng Xu, Vice President of Translational Research at Endeavor Health and lead author of the study, the integration of both monogenic and polygenic evaluations considerably enhances the ability to identify individuals at high risk. Xu likens the monogenic test to a flashlight that illuminates part of the picture, while the combined approach acts like a floodlight, revealing the entire landscape of risk factors. This comprehensive contrast emphasizes the remarkable potential of GenProb-CAD to uncover hidden risks effectively.

Identifying High-Risk Patients

The new test has proven exceptionally effective, discovering a greater number of individuals at significant risk compared to traditional monogenic tests alone. Importantly, the study revealed that patients flagged by the GenProb-CAD test had risks comparable to those identified through conventional diagnostic techniques, such as blood tests and electrocardiograms, thereby reaffirming the test’s clinical relevance. Furthermore, the research found that this new methodology maintains its effectiveness even when considering other known risk factors, including cholesterol levels, allowing for earlier detection and intervention strategies.

Proactive Healthcare Approach

Arman Qamar, director at Endeavor Health's Center for Cardiovascular Personalized Medicine, stated, "This test operates as an early warning system, enabling us to identify individuals likely to develop heart disease before any symptoms materialize." By establishing such proactive measures, healthcare providers can implement preventive strategies and potentially avert serious cardiovascular events through timely interventions.

Commitment to Genetics in Healthcare

Endeavor Health has championed genetic testing since 2014 via its Advanced Primary Care division, which stands as one of the largest clinical genomics programs in the United States. More than 80,000 patients have participated in this initiative, which has led to earlier diagnoses, prevention tactics, and tailored treatment plans—further solidifying the organization’s commitment to utilizing genetics for enhancing overall patient care.

For more information about GenProb-CAD testing and to evaluate eligibility, interested parties are encouraged to contact Endeavor Health directly at 847-570-GENE. It’s significant to note that PRS testing is currently not covered by insurance plans, prompting an increased focus on individual accessibility to this advanced screening option.

Conclusion

The GenProb-CAD test from Endeavor Health stands as a testament to the transformative potential of integrating genomic data into everyday healthcare practices. By providing enhanced risk assessments for coronary artery disease, the endeavor reflects a pioneering move towards personalized medicine, ultimately aiming to save lives by preventing heart disease before it strikes.